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SUMMARY
 
An attenuated 
 
Plasmodium falciparum
 
 sporozoite (
 
Pf
 
SPZ)
vaccine is under development, in part, based on studies in mice
with 
 
P. berghei
 
. We used 
 
P. berghei
 
 and 
 
P. yoelii
 
 to study vaccine-
induced protection against challenge with a species of parasite
different from the immunizing parasite in BALB/c mice. One-
hundred percent of mice were protected against homologous
challenge. Seventy-nine percent immunized with attenuated
 
P. berghei 
 
sporozoite (
 
Pb
 
SPZ) 
 
(six experiments)
 
 were protected
against challenge with 
 
P. yoelii 
 
sporozoite (
 
Py
 
SPZ), and 63%
immunized with attenuated 
 
Py
 
SPZ 
 
(three experiments)
 
 were pro-
tected against challenge with 
 
Pb
 
SPZ. Antibodies in sera of immu-
nized mice only recognized homologous sporozoites and could not
have mediated protection against heterologous challenge. Immuniza-
tion with attenuated 
 
Py
 
SPZ or 
 
Pb
 
SPZ induced CD8
 
+
 
 T cell-
dependent protection against heterologous challenge. Immunization
with attenuated 
 
Py
 
SPZ  induced CD8
 
+
 
 T cell-dependent
protection against homologous challenge. However, homologous
protection induced by attenuated 
 
Pb
 
SPZ was not dependent on
CD8
 
+
 
 or CD4
 
+
 
 T cells, and depletion of both populations only
reduced protection by 36%. Immunization of C57BL/10 mice
with 
 
Pb
 
SPZ induced CD8
 
+
 
 T cell-dependent protection against
 
P. berghei
 
, but no protection against 
 
P. yoelii
 
. The cross-protection
data in BALB/c mice support testing a human vaccine based on
attenuated 
 
Pf
 
SPZ for its efﬁcacy against 
 
P. vivax.
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INTRODUCTION
 
In 1967 it was reported that immunization of A/J mice
with radiation-attenuated 
 
Plasmodium berghei 
 
sporozoites
(
 
Pb
 
SPZ) protected the mice against malaria (1). Several
years later, it was reported that humans immunized by
exposure to radiation-attenuated 
 
P. falciparum
 
 sporozoites
(
 
Pf
 
SPZ) (2–4) were also protected. There now is a major
effort to develop an attenuated sporozoite (SPZ) vaccine to
protect humans against
 
 P. falciparum
 
, the malaria parasite
responsible for greater than 98% of the 1–3 million deaths
caused by malaria annually (5). It is not known if immuni-
zation with attenuated 
 
Pf
 
SPZ will protect against exposure
to 
 
P. vivax
 
,
 
 P. malariae 
 
or
 
 P. ovale
 
, the three other 
 
Plasmodium
 
species that infect humans. One individual was immunized
with 
 
Pf
 
SPZ, shown to be protected against 
 
P. falciparum
 
,
and then challenged with 
 
P. vivax
 
 SPZs, and shown not to
be protected (6), raising the possibility that there may not
be cross-protection. Determination of cross-protection in
humans must await clinical trials. However, because of the
importance murine studies have played in providing the
foundation for human studies with attenuated SPZs, we
have used two rodent malaria parasites, 
 
P. berghei 
 
and
 
P. yoelii
 
, to study cross-protection in mice. The results
indicate that there is signiﬁcant cross-protection, and that
different immune responses may be active against closely
related parasite species.
 
MATERIALS AND METHODS
 
Mice
 
Female, 6- to 8-week-old BALB/CByJ and C57B1/l0 mice
from Jackson Laboratories (Bar Harbor, ME, USA) were
used in this study.
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Parasites and immunizations
 
Sporozoites of 
 
P. berghei 
 
(ANKA) (7) and 
 
P. yoelii
 
(17NL, 1.l clone) (8) were produced in laboratory-bred and
infected 
 
Anopheles stephensi 
 
mosquitoes. Sporozoites for
immunization were separated from infected mosquitoes
using a renografﬁn discontinuous gradient as previously
described (7). Sporozoites were prepared from infected
mosquitoes that had been exposed to 10  000 rad from a
 
137
 
Ce source. Harvested SPZs were counted, diluted to the
required concentration in M199 containing 5% normal
mouse serum, and a volume of 0·2  mL was injected i.v.
through the tail vein. Mice received multiple doses at 2-week
intervals consisting of 7 
 
×
 
 10
 
4
 
 irradiated SPZs as the ﬁrst
dose and 3 
 
×
 
 10
 
4
 
 irradiated SPZs as subsequent doses.
In challenge experiments, hand-dissected, infected mosquito
glands were triturated in medium to obtain SPZs. Challenge
doses varied from 1 to 10 
 
× 
 
10
 
3
 
 nonirradiated SPZs and
were injected i.v. Minimum infective doses and the 50%
infectious dose (ID
 
50
 
) of SPZs used to challenge the immune
animals were determined during most challenges by making
ﬁvefold dilutions of the challenge inocula.
 
Antibody responses
 
An indirect ﬂuorescent antibody test (IFAT) was used to
detect antibodies to 
 
P. yoelii
 
 and 
 
P. berghei
 
 SPZs in sera of
mice by methods previously described (8). Brieﬂy in the
IFAT, diluted sera were reacted with air-dried SPZs and end
point titres were detected using ﬂuorescein isothiocyanate
(FITC)-labelled rabbit anti-mouse immunoglobulin.
 
Protection against challenge
 
Two weeks after the last immunization, mice were challenged
by i.v. inoculation in the tail vein with viable 
 
P. yoelii
 
 or
 
P. berghei
 
 SPZs. Giemsa stained blood ﬁlms were examined
with a light microscope under an oil immersion objective (1000
 
×
 
)
for the presence of asexual erythrocytic stage parasites.
Mice showing no parasites in their blood for 15 days follow-
ing challenge with infective SPZs were designated as negative.
 
Depletion of CD8
  
+ + + +
 
 T lymphocytes
 
To determine if CD8
 
+
 
 T cells were required for protective
immunity, we depleted mice of CD8
 
+
 
 T lymphocytes just
prior to challenge. Mice immunized with ﬁve doses of
irradiated SPZs were given three 0·5-mg i.p. injections of
the mAb 19/178 at 24-h intervals to deplete them of CD8
 
+
 
 T
lymphocytes as previously described (9). Peripheral
lymphocyte samples were prepared and analysed for deple-
tion of the population carrying the CD8
 
+
 
 T cell marker in a
ﬂuorescent-activated cell sorter (FACS). The mice were
challenged with infective SPZs 4 days later. Treatment with
mAB 19/178 was continued every third day after challenge
until patency occurred. Control immunized mice were
injected with the same quantities of rat immunoglobulin.
 
Calculation of the ID
 
50
 
 and challenge units
 
Because the infectivity of individual preparations of SPZs
may vary, the infectivity of the SPZs used for challenge
was monitored during challenge in some of the experiments
(Tables 1–3). Serial dilutions of SPZs were inoculated into
groups of naive mice to determine the ID
 
50
 
 (the number
of SPZs needed to infect 50% of injected normal mice) of the
SPZs used in the challenge. For 
 
Py
 
SPZ, 200, 40, 8 or 1·6
SPZs were injected i.v. into groups of six mice. For 
 
Pb
 
SPZ,
1000, 200 or 40 SPZs were injected i.v. into groups of six
mice as 
 
Py
 
SPZs are more infectious than 
 
Pb
 
SPZ. To obtain
the ID
 
50
 
, we took the natural logarithm (ln) of the doses
tested. We used logistic regression to model the log odds of
infection vs. the log-transformed doses. The ID
 
50
 
 is the log
Table 1 Cross-protection between PySPZ and PbSPZ in BALB/c 
mice
Immunization
Challenge
SPZsa
Number protected/
number challenged
Total (%
protected) Experiment 1 Experiment 2
Irradiated 
PySPZ
P. yoelii 6/6 7/7 13/13 (100)
Irradiated 
PySPZ
P. berghei 4/6 3/7 7/13 (54)
Irradiated 
PbSPZ
P. berghei 6/6 7/7 13/13 (100)
Irradiated 
PbSPZ
P. yoelii 5/6 7/7 12/13 (92)
Naive P. yoelii 0/6 0/7 0/13 (0)
Naive P. berghei 0/6 0/7 0/13 (0)
Mice were immunized i.v. with ﬁve doses of radiation-attenuated 
PySPZ or PbSPZ. Two weeks after the last immunization, mice 
were challenged with infective SPZ. The number of PySPZ used for 
the challenge was 5 × 103, and that for PbSPZ was 10 × 103. The 
units of ID50 were calculated by dividing the challenge dose by the 
ID50. aAlthough we did SPZ titrations to determine the infectivity 
of the SPZs used in Experiments 1 and 2, we only obtained enough 
data points (see Materials and methods) in one experiment for each 
parasite to calculate the ID50. The ID50 for P. yoelii in Experiment 
1 was 3·3 SPZs (95% CI 1·2−8·8), and the number of P. yoelii ID50 
units contained in the 5 × 103 SPZs used for this challenge was 
1525·7 (95% CI 569·1−4090·3). The ID50 for P. berghei in 
Experiment 2 was 370 SPZs (95% CI 126·5–1082·1), and the 
number of P. berghei ID50 units contained in the 10 × 103 SPZs used 
for this challenge was 27·0 (95% CI 9·2–79·1).Journal compilation © 2007 Blackwell Publishing Ltd, Parasite Immunology, 29, 559–565 561
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dose at which the probability of infection is 0·5. To be
acceptable for calculation of the ID50, at least two consecutive
dilutions had to have less than 100% and greater than 0
infectivity. This is because the log of the odds for these
results had to be ﬁnite. Conﬁdence intervals for this point
estimate were calculated using the asymptotic variance
obtained by the delta method; log ID50 values were expo-
nentiated back to numbers of SPZs. After determining the
ID50 for the individual SPZ preparation, the number of ID50
units contained in the challenge dose was calculated by
dividing the challenge dose by the calculated ID50.
RESULTS
Antibody responses
Table 4 shows that immunization with irradiated PySPZ or
PbSPZ resulted in the production of high antibody titres to
the parasite used for the immunization, but no cross-reacting
antibodies to the other species.
Cross-protection in BALB/c mice
Two weeks after the last immunization with radiation-
attenuated SPZs, mice were challenged by i.v. injection of
infective PySPZ or PbSPZ. In two challenge experiments,
the number of PySPZ and PbSPZ used for challenge was
5 × 103 and 10 × 103, respectively. In all challenges, 100% of
naive mice became infected. In these two challenges, protection
against challenge with PySPZ or PbSPZ was 100% in groups
Table 2 Protective immunity in BALB/c mice immunized with radi-
ation-attenuated PySPZ with and without CD8+ T cell depletion
Immunization
T cell 
depletion
Challenge
SPZsa
Number protected/
number challenged
(% protected)
Irradiated PySPZ Control P. yoelii 6/6 (100)
Irradiated PySPZ CD8+ P. yoelii 0/6 (0)
Irradiated PySPZ Control P. berghei 5/6 (83)
Irradiated PySPZ CD8+ P. berghei 0/7 (0)
Naive − P. yoelii 0/6 (0)
Naive − P. berghei 0/6 (0)
Groups of BALB/c mice were immunized with ﬁve doses of 
radiation-attenuated PySPZ. Two weeks after the last 
immunization, mice were injected with anti-CD8 mAbs or a control 
antibody prior to challenge with infective SPZs. The challenge dose 
for P. berghei was 4 × 103 SPZs, and for P. yoelii was 103 SPZs.
aThe ID50 for P. yoelii was 13·6 SPZs (95% CI 5·4–34·0), and the 
number of P. yoelii ID50 units contained in the 1 × 103 SPZs used 
for the challenge was 73·7 (95% CI 29·4−185·1). The ID50 units for 
the P. berghei challenge could not be determined (see Materials 
and Methods).
Table 3 Protective immunity in BALB/c mice immunized with irradiated PbSPZs with and without CD8+ T cell depletion
Immunization
T cell 
depletion
Challenge
SPZsa
Number protected/number challenged
Total 
(% protected) Experiment 1 Experiment 2
Irradiated PbSPZ Control P. berghei ND 5/5 5/5 (100)
Irradiated PbSPZ CD8+ P. berghei ND 5/5 5/5 (100)
Irradiated PbSPZ Control P. yoelii 7/7 3/5 10/12 (83)
Irradiated PbSPZ CD8+ P. yoelii 0/6 0/6 0/12 (0)
Naive − P. berghei ND 0/5 0/5 (0)
Naive − P. yoelii 0/6 0/6 0/12 (0)
Groups of BALB/c mice were immunized with ﬁve doses of radiation-attenuated PbSPZ. Two weeks after the last immunization, mice were 
injected with anti-CD8 mAbs or control antibody prior to challenge with infective SPZs. The challenge dose for P. berghei was 4 × 103 infective 
SPZs, and for P. yoelii was 1 × 103 SPZs. aThe ID50 for P. yoelii used in Experiment 1 was 17·9 SPZs (95% CI 7·6−42·2), and the number of 
P. yoelii ID50 units contained in the 1 × 103 SPZs used for this challenge was 55·9 (95% CI 23·7−132·0). ID50 units for the P. yoelii used in 
Experiment 2 and the P. berghei challenge could not be determined (see Materials and Methods).
ND, not done.
Table 4 Antibodies in BALB/c mice to PySPZ and PbSPZ after 
immunization with radiation-attenuated PySPZ and PbSPZ
Immunization SPZs in IFAT IFAT titre
Irradiated PySPZ P. yoelii 2048
Irradiated PySPZ P. berghei  < 8
Irradiated PbSPZ P. berghei 4096
Irradiated PbSPZ P. yoelii  < 8
Mice were immunized i.v. with ﬁve doses of radiation-attenuated 
PySPZ or PbSPZ. Two weeks after the last immunization, just prior 
to challenge with infective SPZs, pooled sera were tested for 
antibodies to air-dried PySPZ or PbSPZ by IFAT.562 Journal compilation © 2007 Blackwell Publishing Ltd, Parasite Immunology, 29, 559–565
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that received the same parasite species for immunization
and challenge (homologous immunization and challenge)
(13 out of 13 mice protected for both parasites) (Table 1).
However, BALB/c mice immunized with radiation-attenuated
SPZs of either parasite strain showed different levels of
cross-protection against the heterologous parasite species
challenge. In two experiments, the level of cross-protection
obtained when mice immunized with attenuated PbSPZs
were challenged with PySPZs was greater (12 out of 13 mice
protected, 92·3%) than when mice immunized with attenuated
PySPZs were challenged with PbSPZ (7 out of 13 mice
protected, 54%); P = 0·073, Fisher’s exact test, two-sided.
This difference occurred despite signiﬁcantly higher infectivity
of the PySPZ (mean ID50 = 10·6)  vs.  PbSPZ (mean
ID50 = 571·1); P = 0·0047, independent samples t-test.
Mechanisms of cross-protection in BALB/c mice
In BALB/c mice, CD8+ T cells have been shown to be
responsible for the immunity against PySPZ after immu-
nization with radiation-attenuated PySPZ (8–10), while
protection induced in BALB/c mice after immunization with
irradiated PbSPZ is independent of CD8+ T cells (11).
To determine whether the same immune mechanisms were
responsible for the cross-protection between P. yoelii and
P. berghei, we injected immunized mice with an anti-CD8
mAb and then challenged the mice with infective SPZs. The
FACS analysis conﬁrmed that injection of the mAb resulted
in depletion of more than 99% of the CD8+ T cells (data
not shown). Depletion of CD8+ T cells in BALB/c mice
immunized with attenuated PySPZ eliminated protection
against challenge with homologous (P. yoelii) and heterologous
(P. berghei) SPZs (Table  2). In mice immunized with
attenuated  PbSPZs, treatment with anti-CD8 antibodies
had no effect on challenge with homologous (P. berghei)
SPZs, but it eliminated protection against heterologous
(P. yoelii) SPZs (Table 3).
Since CD8+ T cell depletion did not affect protective efﬁcacy
in BALB/c mice immunized with radiation-attenuated
PbSPZ and challenged with PbSPZs (Table 3), we assessed
the effect of CD4+ T cell depletion in these mice (Table 5).
Depletion of CD4+ T cells had no effect on protection
(Table 5), but depletion of both CD4+ and CD8+ T cells had
a modest effect on protective efﬁcacy (Table 5). CD4+ T cell
depletion reduced, but did not eliminate protection against
challenge with PySPZ.
Cross-protection between the two parasite species 
in C57BL/10 mice
In BALB/c mice immunized with radiation-attenuated
PbSPZ, CD8+ T cells are not required for protection against
PbSPZ challenge (11,12). However, in A/J (H-2a) mice
immunized with radiation-attenuated PbSPZ, CD8+ T cells
are required for protection (12,13). Since the mechanism of
protection against P. berghei varied among different mouse
species, we wanted to determine if cross-protection extended
to another mouse strain. We immunized C57BL/10 (H-2b)
mice with irradiated P. berghei to determine the mechanism
of protection induced in this mouse strain against homologous
challenge and also to determine if mice immunized with
irradiated P. berghei showed cross-protection against PySPZ.
In this mouse strain, C57BL/10 (H-2b), protection against
the homologous P. berghei challenge was dependent on
CD8+ T cells (Table 6). Furthermore, C57BL/10 (H-2b)
mice immunized with irradiated P. berghei did not show
cross-protection against PySPZ (Table 6).
DISCUSSION
There were several major new ﬁndings in these studies.
There was signiﬁcant cross-protection between P. yoelii and
P. berghei in BALB/c mice (Tables 1–3 and 5), antibodies
against SPZs did not play a role in the cross-protection and
Table 5 Protective immunity in BALB/c mice immunized with radiation-attenuated PbSPZ with and without CD8+ and/or CD4+ T cell depletion
Immunization
T cell 
depletion
Challenge 
SPZs
Number protected/number challenged
Total 
(% protected) Experiment 1 Experiment 2
Irradiated PbSPZ Control P. berghei 7/7 7/7 14/14 (100)
Irradiated PbSPZ CD4+ P. berghei 7/7 ND 7/7 (100)
Irradiated PbSPZ CD4+ and CD8+ P. berghei 5/7 4/7 9/14 (64)
Irradiated PbSPZ Control P. yoelii 4/7 5/7 9/14 (64)
Irradiated PbSPZ CD4+ P. yoelii 2/7 2/7 4/14 (29)
Naive − P. berghei 0/7 0/7 0/14 (0)
Naive − P. yoelii 0/7 0/7 0/14 (0)
Groups of BALB/c mice were immunized with ﬁve doses of radiation-attenuated PbSPZ and depleted of either T cells expressing CD4+ or 
T cells expressing CD4+ and CD8+ markers, and challenged with 7 × 103 PbSPZ or 1 × 103 PySPZ.Journal compilation © 2007 Blackwell Publishing Ltd, Parasite Immunology, 29, 559–565 563
No claim to original US government works
Volume 29, Number 11, November 2007 Cross-protection between Plasmodium species
the immune mechanisms required for protection against
homologous challenge, but not heterologous challenge, in
BALB/c mice were apparently different for P. yoelii (Table 2)
and P. berghei (Tables 3 and 5).
The potentially most important ﬁnding was the cross-
protection. One-hundred percent of mice were protected
against homologous challenge. Thirty-one of 39 (79%)
BALB/c mice immunized with attenuated PbSPZ were
protected against challenge with PySPZ, and 12 of 19 (63%)
BALB/c mice immunized with attenuated PySPZ were
protected against challenge with PbSPZ (Tables 1–3 and 5).
Mice immunized with PySPZ did not produce antibodies
that recognized PbSPZ, and mice immunized with PbSPZ
did not produce antibodies that recognized PySPZ (Table 4).
Thus, antibodies against SPZs could not have been respon-
sible for the protection against heterologous challenge.
The protection against heterologous challenge in mice
immunized with either radiation-attenuated PySPZ or PbSPZ
was dependent on CD8+ T cells (Tables 2 and 3). When mice
were immunized with radiation-attenuated PySPZ and
challenged with nonirradiated PbSPZ, or immunized with
radiation-attenuated  PbSPZ and challenged with non-
irradiated PySPZ, the protective immunity was eliminated
by treatment of the mice before challenge with an antibody
to CD8+ T cells. These data demonstrated that CD8+ T cells
were required for the cross-protection. The requirement for
T cells to provide protection against heterologous para-
sites was consistent with the ﬁnding that these mice made no
antibodies against the heterologous SPZs (Table 4).
In BALB/c mice immunized with radiation-attenuated
PySPZ, protection against challenge with P. yoelii was
dependent on CD8+ T cells (Table 2). However, in BALB/c
mice immunized with radiation-attenuated PbSPZ, protection
against P. berghei was not eliminated by depletion of either
CD8+ (Table 3) or CD4+ T cells (Table 5) and only modestly
reduced by depletion of both (Table 5). The ﬁnding of lack
of dependence on CD8+ T cells in BALB/c mice immunized
by i.v. injection of irradiated PbSPZ model was ﬁrst
reported more than 16 years ago (11) Interestingly this did
not occur in mice immunized by the bite of irradiated,
PbSPZ-infected mosquitoes (14). Regardless, the other results
have not been previously reported. There are several possible
explanations for why T cell depletion did not reduce
protection against P. berghei in mice immunized with
irradiated PbSPZ. One possibility is that non-T cell immu-
nity is more effective against PbSPZ infection than it is
against P. yoelii. This could be because the infectivity (ID50)
of  PbSPZ is lower than that of PySPZ (Table  1 and see
below), and the parasites are easier to eliminate by non-T
cell mechanisms because fewer of them are infective. This
differential infectivity could explain why, in contrast to
PbSPZ, the protection against PySPZ in these same mice
was eliminated by depletion of CD8+ T cells. Another
explanation for why T cell depletion of mice immunized with
irradiated PbSPZ did not eliminate protection is that
the effect of in vivo T cell depletion on effector T cells could
have been less in mice immunized with irradiated PbSPZ
as compared to after immunization with irradiated PySPZ.
Although the efﬁciency of in vivo depletion of total splenic
CD8+ and CD4+ T cells was 99% in these experiments, we
did not measure antigen-speciﬁc T cell populations responding
to P. berghei or P. yoelii antigens after depletion. Thus, there
remains a possibility that sufﬁcient effector cells remained in
the residual 1% of undepleted total T cells to protect mice
against PbSPZ infection, but not P. yoelii infection. There is
a region, amino acids 281–289 on the P. yoelii circumsporozoite
protein (PyCSP) (SYVPSAEQI) and P. berghei circumspo-
rozoite protein (PbCSP) (SYIPSAEKI), which contains a
protective cytotoxic T lymphocytes (CTL) epitope (15).
Preliminary studies by one of us (W. Weiss, unpublished
data) indicate that the precursor frequency of CD8+ CTLs
responding to the speciﬁc epitopes were 10-fold higher in
BALB/c mice after immunization with irradiated PbSPZ
than with PySPZ. Thus, while in vivo depletion removed 99%
of all CD8+ T cells, it is possible that it removed 10-fold less
CD8+ T effector cells against this protective CTL epitope in
mice immunized with irradiated PbSPZ as compared to
irradiated  PySPZ. Thus, it is possible that T cells were
responsible for protection of BALB/c mice immunized with
irradiated PbSPZ, but that our methods of in vivo depletion
were inadequate to demonstrate this. This line of reasoning
does not explain why in these same mice T cell depletion
eliminated protection against challenge with PySPZ.
Table 6 Protective immunity in C57BL/10 mice immunized with 
radiation attenuated PbSPZ
Immunization
T cell 
depletion
Challenge
SPZs
Number protected/
number challenged
(% protected)
Experiment 1
Irradiated PbSPZ None P. berghei 9/9 (100)
Irradiated PbSPZ None P. yoelii 1/9 (11)
Naive − P. berghei 0/8 (0)
Naive − P. yoelii 1/9 (11)
Experiment 2
Irradiated PbSPZ Control P. berghei 5/5 (100)
Irradiated PbSPZ CD8+ P. berghei 0/5 (0)
Naive − P. berghei 0/5 (0)
Groups of C57BL/10 mice were immunized with ﬁve doses of 
irradiated PbSPZ and challenged with either 5 × 103 PbSPZ or 
PySPZ (Experiment 1). In a second experiment (Experiment 2), 
C57BL/10 mice similarly immunized were depleted of their CD8+ 
T cell subpopulation and challenged with PbSPZ.564 Journal compilation © 2007 Blackwell Publishing Ltd, Parasite Immunology, 29, 559–565
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In mice immunized with irradiated PbSPZ and challenged
with  PySPZ, CD4+ T cell depletion modestly reduced
protection (Table 5), indicating that CD4+ T cells play a role
in this heterologous protection. Interestingly, this effect was
not seen with homologous challenge, but depletion of both
CD8+ and CD4+ T cells reduced protection against homologous
(P. berghei) challenge, again showing that CD4+ T cells do
play some role in protection. This ﬁnding also raises the
possibility of the complementary effects of CD8+ and CD4+
T cells working together. Nevertheless, our ﬁndings and
more than 20  years of research on mice immunized with
irradiated SPZ have demonstrated that CD8+ T cells are the
major effector arm of the immune system, but that CD4+ T
cells also play a role, albeit minor role, and that in some cases,
antibodies can be the major effector immune response (16).
Despite the excellent cross-protection in BALB/c mice,
there was no cross-protection in C57BL/10 mice. It is possible
that the immune response induced with the irradiated
PbSPZ was not strong enough to overcome the highly
infectious PySPZ challenge in the C57BL/10 mice. The high
susceptibility of C57BL/10 mice to PySPZ may also explain
why in some experiments not all mice immunized with
irradiated  PySPZ become protected after challenge with
PySPZ (12,17).
It is generally thought that optimally radiation-attenuated
SPZs pass through the bloodstream to the liver, invade
hepatocytes and partially develop expressing proteins
not expressed in hepatocytes. Many malariologists believe
the CD8+ T cell-dependent protective immunity elicited by
immunization with radiation-attenuated SPZs is primarily
directed against these ‘new’ proteins ﬁrst expressed in
hepatocytes (10,16,17) This view has been based on a report
that ‘over-irradiated’ SPZs do not provide protection even
though they invade hepatoctyes (18), and killed SPZs do not
provide high level of protection (19). Thus, despite the fact
that immunization with PyCSP and PbCSP (11,20–24) based
vaccines elicit CD8+ T cell-dependent protection against
homologous challenge, and transfer of an anti-PyCSP T cell
clone protects against P. yoelii and P. berghei challenge
(15,25), it is thought that these SPZ-derived proteins are not
adequate for the high level of protective immunity seen
after immunization with radiation-attenuated SPZs. These
conclusions are supported by a recent study with mice
transgenic for the PyCSP, and therefore tolerant to the
PyCSP (26,27). When these mice received two doses of
irradiated PySPZ, there was only minimal protection, indi-
cating that PyCSP was important in protective immunity.
However, when these mice received a full immunizing
regimen of three doses of irradiated PySPZ, they were fully
protected against challenge with infectious PySPZ, indicat-
ing that in this model system, immune responses against
the PyCSP were not required for protection. While the data
reported herein do not indicate what antigens are responsible
for the protection, the ﬁndings that a PyCSP T cell clone
was protective against challenge with the heterologous
PbSPZ (15) possibly through the mediation of antigen-
speciﬁc induction of IFNγ is signiﬁcant. The availability of
the genomic sequences of P. yoelii (28) and P. berghei (29),
and gene expression and proteomic analyses should facilitate
the discovery of other antigens involved.
The data presented in this paper re-emphasize the differ-
ences in infectivity of PySPZ and PbSPZ (30–32). The mean
ID50 of P. yoelii was 10·6 (95% CI 6·1–18·3) while that of
P. berghei was 571·1 (249·9–1304·8), indicating that far less
SPZs are needed to produce a P. yoelii infection.
The ﬁnding of cross-protection in mice between P. yoelii
and P. berghei after immunization with radiation-attenuated
SPZs is provocative, but cannot be used to predict what will
occur in humans immunized with radiation-attenuated
SPZs. However, when the radiation-attenuated PfSPZ
vaccine is developed and tested (33), it will be important to
determine if immunization with this vaccine protects against
P. vivax. The data presented herein suggest that cross-
protection could occur. Comparative analyses of the genomes
of P. falciparum, P. vivax, P. yoelii and P. berghei may provide
more insight into the likelihood of cross-protection.
However, there will be no substitute for carefully executed
clinical trials to determine if there is cross-protection.
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